Citizens Reiterates Abivax (ABVX) at Market Outperform After Phase 3 ABTECT Study
Tweet Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $114.00 price target on Abivax (NASDAQ: ABVX).The analyst commented, "Additional ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
